16 September 2026 editorial review · Trial
USTEKID: Ustekinumab in adolescents with recent-onset type 1 diabetes: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Primary NatureMedicine abstract/NIHR report checked against72 randomized and62analyzed populations;49% relative C-peptide effect. Direct ISRCTN retrieval redirected to holding page, so latest registry state could not independently be refreshed.
Sources for this record: Ustekinumab for type 1 diabetes in adolescents (peer-reviewed); ISRCTN14274380: Ustekinumab in adolescents with recent-onset type 1 diabetes (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.